eligibility_summary
Include: Women ≥18 with epithelial ovarian/fallopian/peritoneal or endometrial cancer, platinum‑sensitive recurrence (>6 mo), measurable/evaluable disease, PS 0–1, adequate counts/organ function, contraception. Exclude: recent therapy/surgery/RT, uncontrolled illness or active infection (HBV/HCV/HIV), serious GI disease or recent GI complications, pregnant/nursing, recent serious cardiac/pulmonary disease, CNS mets or carcinomatous meningitis, active 2nd cancer (except cured/low risk).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06040970 tests sacituzumab govitecan plus cisplatin in platinum‑sensitive recurrent epithelial ovarian or endometrial cancers. Sacituzumab govitecan is an antibody–drug conjugate (targeted cytotoxic): a humanized anti–Trop‑2 monoclonal antibody linked to SN‑38 (irinotecan’s active metabolite), a topoisomerase I inhibitor. It binds Trop‑2 on tumor cells, is internalized, and releases SN‑38 to cause DNA single‑strand breaks and apoptosis (with a bystander effect). Cisplatin is a platinum chemotherapeutic that forms DNA intra/interstrand crosslinks, blocking replication and triggering apoptosis. Targets: Trop‑2–overexpressing epithelial tumor cells, topoisomerase I–dependent DNA replication and DNA damage response/repair pathways (NER/HR).